Empo Health exists to empower diabetic patients and providers to improve care, outcomes and quality of life.

Empo Health addresses diabetic foot ulcers (DFUs) that affect 25% of all diabetic patients in their lifetime, leading to 150,000 amputations per year in the US and costing over $80 billion annually in healthcare.

The company has developed the FDA-listed Empo® Footprint in-home imaging scale and the accompanying Empo® Remote Health Link patient monitoring service. This technology empowers patients, podiatrists, and payors to detect early signs of ulcers and intervene at the right time, when treatment is least invasive and most cost-effective.

Empo Health aims to revolutionize healthcare by making monitoring routine and practical for patients and providers alike. Their solutions enhance early detection and management of diabetic foot ulcers, significantly reducing risks of hospitalizations and amputations.

Founded in 2020 by MIT and Stanford-trained technical founders, the company is based in the San Francisco Bay Area.